about
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumorsCharacteristic promoter hypermethylation signatures in male germ cell tumorsInterrogation of a context-specific transcription factor network identifies novel regulators of pluripotencymiR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cellsTesticular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areasPhase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes.Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.Medical treatment of advanced testicular cancer.The future of therapy for nonseminomatous germ cell tumors.Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomasDevelopment and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.Development of a risk stratification system to guide treatment for female germ cell tumors.Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity.A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.Contemporary lymph node counts during primary retroperitoneal lymph node dissection.Evaluation of lymph node counts in primary retroperitoneal lymph node dissection.Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells.Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells.Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells.ID gene expression varies with lineage during differentiation of pluripotential male germ cell tumor cell lines.Treatment of stage I seminoma: is it time to change your practice?Rare de novo germline copy-number variation in testicular cancer.Clinical outcome and predictors of survival in late relapse of germ cell tumorIncidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.Salvage chemotherapy for patients with advanced pure seminoma.Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
P50
Q24791749-50FD3E53-98B2-4381-B48E-83826320B089Q24799928-3DEA0EAD-E10B-4A08-AFE8-CB7CB6AF0981Q27329779-E7F523DC-72CD-4656-8860-2CF2B0B3B314Q28117110-54B6820D-0773-4F62-9A89-F79A80D61F36Q28242844-179BD510-777D-4861-9595-61E8B1FDDD5CQ33387187-1F86091B-935C-4659-A6A0-D25EA6AC0ACDQ34157545-A02B9096-6A2C-4C11-8432-7283C9B858F4Q34516867-FAD91E51-90A8-424F-A7A5-8BF34389E56CQ34749510-203071BD-2582-4AA6-83B1-9B0A75CBD477Q35020149-0030F33C-5045-4B47-94AC-9BF6D78C4196Q35163131-B807A0D6-1B03-49A3-A38C-02460A24299DQ35747651-D79DCB82-F635-4AAD-A0FB-F4E312E03D74Q35857034-2CBC4F4E-7BCA-463E-A5A7-DCD7BFF99142Q36955911-019E1080-C2DD-453E-B7F6-EA4B62E9F24FQ37234745-43416874-6446-4921-B073-B41AA0E54686Q37234753-AF786270-0A39-4026-BC6B-4008A5EA545BQ37617479-4A7E0DB6-B993-4999-A539-AA076EDC9FF3Q37823777-CBE6FD3F-CD1D-4B4C-A828-5DEAF75D225EQ37875412-A0F12E73-F11F-4C51-A7CF-A8108897E78DQ37991059-B862C4E6-E1CA-40BD-8C73-DFAD20A7157EQ37996800-18EBCF3D-3451-489F-A137-468D2AEAB11DQ38046168-EA0E79E7-EED9-40B3-90F2-6961AE8432CDQ38100753-7B801B6C-1C78-490A-98E0-326199DF1B60Q38996788-A5552EFC-25E8-4D06-885D-0B52DA68DDC0Q39313259-5C958FD9-3481-4DC8-B09F-5A93B6921E78Q39852859-56A046CF-21B9-47B6-9D4D-D96F0ECB3572Q40202311-F6860B0B-B630-49CE-922E-4A224DAC1DDFQ40462174-FE7BAF47-3CDF-43A5-8503-C5FDF7916B08Q40625004-FD5EF85B-4F33-4134-A33D-F72A8CB79820Q40718843-43E58A7A-7D1B-4CEF-BB4F-8E21A0C689D9Q40810073-5CD327AC-1102-43A6-A7F4-BF0AA6FF010AQ41594407-8B92CF3F-0350-4892-98CE-BB2A9DF3B5D5Q41768169-84811320-1AB0-44C5-ABEC-7BBF939B51D4Q41863005-E00709B4-E96A-4C4A-8CDE-AD2897D133D0Q42612075-0EE888B2-A526-4B61-B302-9360159EE857Q43545111-807E03F8-BC00-4B5C-A731-BEF94DEED464Q43833826-48A9B6EE-8EBC-4961-ADB9-5F10F606659FQ43843479-BA345254-BE10-4B21-A24E-33429B55773BQ44739426-456C22A7-D352-481D-A8C6-B33A038707C7Q44748837-4D3FCEAA-3B58-4504-8863-FFA3450FFF88
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
George J Bosl
@ast
George J Bosl
@en
George J Bosl
@es
George J Bosl
@nl
George J Bosl
@sl
type
label
George J Bosl
@ast
George J Bosl
@en
George J Bosl
@es
George J Bosl
@nl
George J Bosl
@sl
prefLabel
George J Bosl
@ast
George J Bosl
@en
George J Bosl
@es
George J Bosl
@nl
George J Bosl
@sl
P106
P21
P31
P496
0000-0002-7842-6584